Browse
Submit Data
Databases
API
Help

Dataset Information

13 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Japan colorectal tumor prevention study: clinical trial by low-dose aspirin

ABSTRACT: Interventions: aspirin enteric-coated tablet (100 mg, one tablet daily) for four years Primary outcome(s): The primary endpoint is set as the incidence of newly diagnosed colorectal Index Lesion (adenomas >= 10 mm in diameter, adenomas with high-grade dysplasia, or invasive cancer) during 4 years observation excluding the first year observation. Study Design: Single arm Non-randomized

DISEASE(S): Patients With Colorectal Tumor (adenoma, Carcinoma In Situ)

PROVIDER: 2634032 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Japan colorectal tumor prevention study: clinical trial by low-dose aspirin (J-CAPP Study II)

Project description:Interventions: Medicate Primary outcome(s): The primary endpoint is set as the incidence of newly diagnosed colorectal Index Lesion (adenomas >= 10 mm in diameter, adenomas with high-grade dysplasia, or invasive cancer) during 4 years observation excluding the first-year observation. Study Design: single arm study, open(masking not used), uncontrolled control, single assignment, treatment purpose

| 2615273 | ecrin-mdr-crc

Japan colorectal tumor prevention study: randomized controlled trial by low-dose aspirin

Project description:Interventions: Aspirin (100 mg/day) enteric-coated tablet Placebo tablet / day Primary outcome(s): Only the occurrence of a colorectal tumor (adenoma or cancer) is selected as the primary endpoint. Study Design: Parallel Randomized

| 2616201 | ecrin-mdr-crc

A multicenter observational study for measurement of SNPs in participants of the Japan Polyp Study Cohort

Project description:Primary outcome(s): Interaction between SNPs of ALDH2 and the effectiveness of aspirin in preventing the development of index lesions (ILs: cancers, adenomas with high-grade dysplasia, and adenomas measuring >= 10 mm) at 4 years

| 103893 | ecrin-mdr-crc

Solute carrier family 12 member 2 as a proteomic and histological biomarker of dysplasia and neoplasia in ulcerative colitis

Project description:Ulcerative colitis (UC) patients have a greater risk of developing colorectal cancer through inflammation-dysplasia-carcinoma sequence of transformation. The histopathological diagnosis of dysplasia is therefore of critical clinical relevance, but dysplasia may be difficult to distinguish from inflammatory changes. A proteomic pilot study on 5 UC colorectal dysplastic patients highlighted proteins differentially distributed between paired dysplastic, inflammatory and normal tissues. The best candidate marker was selected and immunohistochemistry confirmation was performed on AOM/DSS mouse model lesions, 37 UC dysplasia, 14 UC cancers, 23 longstanding UC, 35 sporadic conventional adenomas, 57 sporadic serrated lesions and 82 sporadic colorectal cancers. Differential proteomics found 11 proteins significantly more abundant in dysplasia compared to inflammation, including Solute carrier family 12 member 2 (SLC12A2) which was confidently identified with 8 specific peptides and was below the limit of quantitation in both inflammatory and normal colon. SLC12A2 immunohistochemical analysis confirmed the discrimination of preneoplastic and neoplastic lesions from inflammatory lesions in mice, UC and in sporadic contexts. A specific SLC12A2 staining pattern termed “loss of gradient” reached 89% sensitivity, 95% specificity and 92% accuracy for UC-dysplasia diagnosis together with an inter-observer agreement of 95.24% (multirater κfree of 0.90; IC95%: 0.78 – 1.00). Such discrimination could not be obtained by Ki67 staining. This specific pattern was also associated with sporadic colorectal adenomas and cancers. We found a specific SLC12A2 immunohistochemical staining pattern in precancerous and cancerous colonic UC-lesions which could be helpful for diagnosing dysplasia and cancer in UC and non-UC patients.

2020-09-16 | PXD018679 | Pride

DNA methylation changes in advanced sessile serrated adenomas that precede progression to dysplasia

Project description:The CpG island methylator phenotype is common in both BRAF mutant colorectal cancer and their precursors, the sessile serrated adenoma (SSA). SSAs acquire dysplasia immediate prior to progressing to invasive cancer. Here we examine the methylome of the remnant non-dysplastic portion of dysplastic sessile serrated adenomas to identify changes that occur immediately prior to the development of overt histological dysplasia.

2019-07-11 | E-MTAB-7854 | biostudies-arrayexpress

Illumina 850k methylation data from colon polyps

Project description:The tubular adenoma sample cohort (accrued by Janssen Pharmaceuticals) consisted of 127 high-risk baseline adenoma samples acquired retrospectively by Avaden Biosciences. High risk patients are defined here as presenting a tubular adenoma ? 10mm, 3 or more adenomas, adenomas with villous histology or adenomas showing high-grade dysplasia based on Lieberman et al. Patients with familial adenomatous polyposis (FAP) and Lynch syndrome were excluded. All patients received at least one baseline colonoscopy for which clinical and pathological records were available. Adenoma tissue was available as archival, formalin-fixed, paraffin-embedded (FFPE) blocks.

2023-08-09 | GSE233604 | GEO

Illumina 450k methylation data from colon polyps

2023-08-09 | GSE233603 | GEO

Affymetrix array expression data from colon polyps

2023-08-09 | GSE233602 | GEO

Gene Expression Profiling of Mismatch Repair Deficient Intestinal Stem Cells

Project description:We have generated a gene signature of mismatch repair (MMR) deficient intestinal stem cells (ISCs) using whole-genome transcriptomics and proteomics from murine intestinal stem cells and epithelial non-stem cells in a Lynch syndrome mouse model (Msh2-fl/fl;Villin-Cre). Then we have validated this signature in RNA-seq data from LS normal unaffected mucosa (UM), adenomas (AD) and adenomas with high-grade dsyplasia (AD-HGD) and tumors (T). MMR status for LS tumors and adenomas with high-grade dysplasia was categorized as KO, for unaffected mucosa as HET and FAP samples as WT.

2021-06-01 | GSE153385 | GEO

Novel single nucleotide polymorphism markers for low dose aspirin-associated small bowel bleeding

Project description:Blood from 17 patients taking enteric-coated low-dose aspirin (LDA) and with suspected bleeding from small intestine and 18 control patients taking aspirin were analyzed. Results provide insight into the risk for aspirin-induced small bowel bleeding.

2013-11-08 | GSE52155 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data